Treatment Area
Abdomen, Thigh or Upper Arm
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.

Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.

Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Start with a consultation and discuss which treatment category may be relevant to your concern.
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.
Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.
Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.
Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.
Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.
Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.
A doctor-led option for eligible patients, with once-weekly administration and regular progress monitoring.
Mounjaro (tirzepatide) is a once-weekly prescription injectable medication used for type 2 diabetes and weight management. It works by activating GIP and GLP-1 receptors to help regulate blood sugar, control appetite and support weight loss as part of a personalised treatment plan.
Mounjaro is prescribed to support blood sugar management in adults with type 2 diabetes and weight management in eligible patients, alongside appropriate dietary and lifestyle changes.
Mounjaro activates two hormone pathways, GIP and GLP-1, to help regulate blood sugar, reduce appetite and slow stomach emptying. This helps patients feel fuller for longer, reduce food intake and support weight management.
Abdomen, Thigh or Upper Arm
Once-Weekly Subcutaneous Injection
A brief needle prick or mild discomfort may occur at the injection site.
No routine recovery period is required. Temporary gastrointestinal side effects may occur.
Treatment usually begins at 2.5 mg once weekly for 4 weeks, followed by 5 mg once weekly. Your doctor may gradually adjust the dose at intervals of at least 4 weeks, depending on your response and tolerability. The maximum recommended dose is 10 mg once weekly.
Changes in appetite, blood sugar and body weight vary between individuals. Regular follow-up is recommended to assess progress and adjust treatment where necessary.
A medical consultation is required before starting Mounjaro. Inform your doctor about your medical history, existing health conditions, current medications, pregnancy plans and any previous reactions to injectable medications. Mounjaro is a prescription-only medication and should be used under medical supervision. Your doctor will determine whether it is suitable for you.
Seek urgent medical attention for severe, persistent abdominal pain or signs of a serious allergic reaction.